CoronaryAtlas logo
CoronaryAtlas
Endothelin-1
Pathway / Endothelial activation & erosion

Endothelin-1

EDN1peptide

ET-1 drives endothelial activation, excessive vasoconstriction, and endocardial injury during acute MI, with predictive value for endothelial progenitor cell mobilization post-infarction.

Pathway placement
Cascade stepEndothelial activation & erosion
Confidencehigh
RationaleEndothelin-1 mediates endothelial dysfunction, vasoconstriction, and endocardial signaling in acute MI.
Also acts inSystemic / off-pathway, Platelet activation
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableNo
Antibody tractableYes
EnsemblENSG00000078401

Type I vs Type II discrimination

ScoresShared / rises in both
R — rupture / Type-I
67
C — confounder / Type-II
67
A — assay feasibility
66
E — evidence strength
95
T1DI (composite)
31
Specificity differential (R−C)0
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationmag 3
2anemia / acute blood lossn/a
3hypovolemia / dehydrationmag 1
4tachyarrhythmiamag 2
5hypoxemia / respiratory failuremag 2
6hypertensive emergencymag 2
7high-demand / peri-operative stressmag 2
Coverage: 6/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 13 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Plasma (EDTA; peptidase-labile — chilled + protease inhibitor)
Collection tube
K2-EDTA, chilled plastic (lavender-top) · Serum separator (gold/red-top, SST)
Method / principle
Competitive/sandwich immunoassay or LC-MS/MS
Reagent / substrate
Anti-peptide antibody; or isotope-labeled internal standard (MS)
Platform
Immunoassay / LC-MS/MS
Turnaround · availability
Send-out / research · Research-grade

Literature evidence(8)

Clinical trials(1)